Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence.
This open longitudinal study investigated the prevalence of depressed sexual potency by monitoring erectile dysfunction using nocturnal penile tumescence (NPT) in 51 consecutive men with hyperprolactinemia (41 macroprolactinomas and 10 microprolactinomas) and evaluated potential reversibility of sexual failure after 6 months of treatment with cabergoline. Fifty-one healthy men served as controls. Compared with controls, the patients with either micro- or macroprolactinoma had low testosterone levels with severe alterations of erectile function. Testosterone deficiency was present in 73.2% of macro- and 50% of microprolactinomas; reduced libido and sexual potency were referred by 53.6% of macroprolactinomas, 50% of microprolactinomas, and none of controls. Fewer than three erectile events per night by NPT were found in 96.7% of patients and 13.7% of controls (P < 0.0001). After 6 months of cabergoline treatment, prolactin levels normalized in 74.5% of patients: 73.2% of macroprolactinomas and 80% of microprolactinomas. Testosterone levels normalized in 68.6% of patients, whereas NPT normalized in 60.6% of patients who had normalized prolactin levels and in 7.7% of patients who did not. In conclusion, at study entry, 50% of the patients complained of sexual disturbances, 96.7% of whom had an impairment of erectile events per night compared with 13.7% of controls. Six months of treatment with cabergoline normalized testosterone levels in most cases, thus restoring and maintaining during treatment the capability of normal sexual activity in hyperprolactinemic males.
De Rosa
Michele
M
Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, 80131 Naples, Italy.
Zarrilli
Stefano
S
Vitale
Giovanni
G
Di Somma
Carolina
C
Orio
Francesco
F
Tauchmanova'
Libuse
L
Lombardi
Gaetano
G
Colao
Annamaria
A
D000328:Adult; D000077465:Cabergoline; D016022:Case-Control Studies; D002940:Circadian Rhythm; D018491:Dopamine Agonists / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D004873:Ergolines / Q000008:administration & dosage*; D006801:Humans; D006966:Hyperprolactinemia / Q000150:complications*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D010410:Penile Erection; D013739:Testosterone / Q000097:blood; D016896:Treatment Outcome
D018491:Dopamine Agonists; D004873:Ergolines; D013739:Testosterone; D000077465:Cabergoline